Certain Products Containing Tirzepatide and Products Purporting To Contain Tirzepatide; Notice of a Commission Determination Not To Review an Initial Determination Granting a Motion To Amend the Complaint and Notice of Investigation, 51549-51550 [2024-13370]

Download as PDF lotter on DSK11XQN23PROD with NOTICES1 Federal Register / Vol. 89, No. 118 / Tuesday, June 18, 2024 / Notices Written submissions must be filed no later than by close of business on July 12, 2024. Persons filing written submissions must file the original document electronically on or before the deadlines stated above. The Commission’s paper filing requirements in 19 CFR 210.4(f) are currently waived. 85 FR 15798 (Mar. 19, 2020). Submissions should refer to the investigation number (‘‘Inv. No. 337–TA–1313’’) in a prominent place on the cover page and/or the first page. (See Handbook for Electronic Filing Procedures, https://www.usitc.gov/ documents/handbook_on_filing_ procedures.pdf.). Persons with questions regarding filing should contact the Secretary (202–205–2000). Any person desiring to submit a document to the Commission in confidence must request confidential treatment by marking each document with a header indicating that the document contains confidential information. This marking will be deemed to satisfy the request procedure set forth in Rules 201.6(b) and 210.5(e)(2) (19 CFR 201.6(b) & 210.5(e)(2)). Documents for which confidential treatment by the Commission is properly sought will be treated accordingly. Any non-party wishing to submit comments containing confidential information must serve those comments on the parties to the investigation pursuant to the applicable Administrative Protective Order. A redacted non-confidential version of the document must also be filed simultaneously with any confidential filing and must be served in accordance with Commission Rule 210.4(f)(7)(ii)(A) (19 CFR 210.4(f)(7)(ii)(A)). All information, including confidential business information and documents for which confidential treatment is properly sought, submitted to the Commission for purposes of this investigation may be disclosed to and used: (i) by the Commission, its employees and Offices, and contract personnel (a) for developing or maintaining the records of this or a related proceeding, or (b) in internal investigations, audits, reviews, and evaluations relating to the programs, personnel, and operations of the Commission including under 5 U.S.C. appendix 3; or (ii) by U.S. Government employees and contract personnel, solely for cybersecurity purposes. All contract personnel will sign appropriate nondisclosure agreements. All nonconfidential written submissions will be available for public inspection on EDIS. This action is taken under the authority of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), VerDate Sep<11>2014 17:57 Jun 17, 2024 Jkt 262001 and in part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: June 12, 2024. Lisa Barton, Secretary to the Commission. [FR Doc. 2024–13333 Filed 6–17–24; 8:45 am] BILLING CODE 7020–02–P INTERNATIONAL TRADE COMMISSION [Investigation No. 337–TA–1377] Certain Products Containing Tirzepatide and Products Purporting To Contain Tirzepatide; Notice of a Commission Determination Not To Review an Initial Determination Granting a Motion To Amend the Complaint and Notice of Investigation International Trade Commission. ACTION: Notice. AGENCY: Notice is hereby given that the U.S. International Trade Commission (‘‘Commission’’) has determined not to review an initial determination (‘‘ID’’) (Order No. 16) of the presiding administrative law judge (‘‘ALJ’’) granting a motion to amend the complaint and notice of investigation to name an additional respondent. FOR FURTHER INFORMATION CONTACT: Edward S. Jou, Esq., Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW, Washington, DC 20436, telephone (202) 205–3316. Copies of non-confidential documents filed in connection with this investigation may be viewed on the Commission’s electronic docket (EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email EDIS3Help@usitc.gov. General information concerning the Commission may also be obtained by accessing its internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission’s TDD terminal, telephone (202) 205–1810. SUPPLEMENTARY INFORMATION: The Commission instituted this investigation on November 27, 2023, based upon a complaint filed on behalf of Eli Lilly and Company (‘‘Eli Lilly’’) of Indianapolis, Indiana. 88 FR 82914–15 (Nov. 27, 2023). The complaint, as supplemented, alleges violations of section 337 based upon the importation into the United States and the sale of certain products containing tirzepatide or purporting to contain tirzepatide by SUMMARY: PO 00000 Frm 00058 Fmt 4703 Sfmt 4703 51549 reason of false designation of source and false and misleading advertising, the threat or effect of which is to destroy or substantially injure an industry in the United States, and based upon the importation into the United States, the sale for importation, and the sale within the United States after importation of certain products containing tirzepatide or purporting to contain tirzepatide by reason of infringement of U.S. Trademark No. 6,809,369. Id. The complaint also alleges that a domestic industry exists pursuant to subsection (a)(2) of section 337. Id. The Commission’s notice of investigation named as respondents Arctic Peptides LLC of Akeny, Iowa; Audrey Beauty Co. of Hong Kong, China; Biolabshop Limited of Lancaster, United Kingdom; Mew Mews Company Limited of Hong Kong, China; Strate Labs LLC of Spring, Texas; Steroide Kaufen of Bialystok, Poland; Super Human Store of Barcelona, Spain; Supopeptide of Cedar Grove, New Jersey; Triggered Supplements LLC of Clearwater, Florida; Unewlife of Cedar Grove, New Jersey; and Xiamen Austronext Trading Co., Ltd. of Fujian, China. Id. at 82915. The Office of Unfair Import Investigations (‘‘OUII’’) is also named as a party in this investigation. Id. Respondents Unewlife, Supopeptide, and Steroide Kaufen were terminated pursuant to withdrawal of the complaint. See Order No. 8 (Mar. 7, 2024), unreviewed by Comm’n Notice (Mar. 21, 2024). Respondents Arctic Peptides LLC; Audrey Beauty Co., Ltd.; Biolabshop Limited; Mew Mews Co. Ltd.; Strate Labs LLC; Super Human Store; Triggered Supplements LLC (d/b/ a The Triggered Brand); and Xiamen Austronext Trading Co., Ltd. (d/b/a AustroPeptide) have been found in default. See Order No. 13 (Apr. 22, 2024), unreviewed by Comm’n Notice (May 15, 2024). On May 21, 2024, the complaint and notice of investigation were amended to add two respondents: Fibonacci Sequence LLC d/b/a GenX Peptides of Houston, Texas; and Paradigm Peptides of Michigan City, Indiana. Order No. 12 (Apr. 22, 2024), unreviewed by Comm’n Notice (May 21, 2024), 89 FR 46159–60 (May 28, 2024). On May 8, 2024, Eli Lilly filed a motion to amend the complaint and notice of investigation to name an additional respondent, Total Compounding Pharmaceuticals of Australia. On that same date, Eli Lilly filed a motion for leave to serve Total Compounding Pharmaceuticals by alternative service via email, which was granted pursuant to Order No. 14 (May E:\FR\FM\18JNN1.SGM 18JNN1 51550 Federal Register / Vol. 89, No. 118 / Tuesday, June 18, 2024 / Notices 13, 2024). On May 15, 2024, OUII filed a response to the motion to amend, which did not oppose the amendment. On May 17, 2024, the ALJ issued the subject ID granting the motion to amend the complaint and notice of investigation to name Total Compounding Pharmaceuticals as a respondent. The ALJ found that Eli Lilly had complied with the requirements of Commission Rule 210.14(b) (19 CFR 210.14(b)) for amendment of the complaint and notice of investigation. See ID at 3–6. No petitions for review of the subject ID were filed. The Commission has determined not to review the subject ID. The complaint and notice of investigation are hereby amended to add respondent Total Compounding Pharmaceuticals. The Commission vote for this determination took place on June 13, 2024. The authority for the Commission’s determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission’s Rules of Practice and Procedure (19 CFR part 210). By order of the Commission. Issued: June 13, 2024. Lisa Barton, Secretary to the Commission. [FR Doc. 2024–13370 Filed 6–17–24; 8:45 am] BILLING CODE 7020–02–P DEPARTMENT OF JUSTICE [OMB Number 1121–0184] Agency Information Collection Activities; Proposed eCollection eComments Requested; Revision of a Currently Approved Collection: School Crime Supplement (SCS) to the National Crime Victimization Survey (NCVS) Bureau of Justice Statistics, Department of Justice. ACTION: 60-Day notice. AGENCY: The Bureau of Justice Statistics, Department of Justice (DOJ) will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. DATES: Comments are encouraged and will be accepted for 60 days until August 19, 2024. lotter on DSK11XQN23PROD with NOTICES1 SUMMARY: VerDate Sep<11>2014 17:57 Jun 17, 2024 Jkt 262001 If you have comments especially on the estimated public burden or associated response time, suggestions, or need a copy of the proposed information collection instrument with instructions or additional information, please contact Alexandra Thompson (email: Alexandra.Thompson@usdoj.gov; telephone: 202–532–5472), Bureau of Justice Statistics, 810 Seventh Street NW, Washington, DC 20531. SUPPLEMENTARY INFORMATION: Written comments and suggestions from the public and affected agencies concerning the proposed collection of information are encouraged. Your comments should address one or more of the following four points: —Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the Bureau of Justice Statistics, including whether the information will have practical utility; —Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; —Evaluate whether and if so, how the quality, utility, and clarity of the information to be collected can be enhanced; and ——Minimize the burden of the collection of information on those who are to respond, including using appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Abstract: The Bureau of Justice Statistics (BJS) 2025 School Crime Supplement (SCS) to the National Crime Victimization Survey (NCVS), cosponsored by the Department of Education’s National Center for Education Statistics (NCES), asks respondents ages 12 through 18 about crimes that occurred at school and other characteristics of school crime. The SCS includes questions on preventive measures used by schools; students’ participation in after school activities; students’ perceptions of safety and belonging in schools; students’ perception of school rules and enforcement of these rules; the presence of weapons, illegal and prescription drugs including opioids, alcohol, and gangs in school; student bullying; haterelated incidents; and attitudinal questions relating to the fear of victimization at school. This FOR FURTHER INFORMATION CONTACT: PO 00000 Frm 00059 Fmt 4703 Sfmt 4703 information helps policymakers; academic researchers; practitioners at the federal, state, and local levels; and special interest groups, who are concerned with crime in schools, make informed decisions about policies and programs. Overview of This Information Collection 1. Type of Information Collection: Revision of a currently approved collection. 2. Title of the Form/Collection: 2025 School Crime Supplement (SCS) to the National Crime Victimization Survey (NCVS). 3. Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: The form number for the questionnaire is SCS–1. The applicable component within the Department of Justice is the Bureau of Justice Statistics (BJS), in the Office of Justice Programs. 4. Affected public who will be asked or required to respond, as well as the obligation to respond: The survey will be administered to persons ages 12 to 18 in NCVS sample households in the United States from January through June 2025. The SCS collects information on the students’ victimization, perceptions of school environment, and safety at school. The survey is voluntary, and respondents are not required to respond. 5. An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: An estimate of the total number of respondents is 5,530 persons ages 12 to 18. Of the 5,530 SCS respondents, 87% or 4,811 are expected to complete the long SCS interview (entire SCS questionnaire) which takes an estimated 17 minutes (0.28 hours) to complete. The remaining 13% or 719 SCS respondents are expected to complete the short interview (i.e. will be screened out for not being in school), which takes an estimated 2 minutes (0.03 hours) to complete. There are an estimated 1,380 annual burden hours associated with this collection. Respondents will be asked to respond to this survey only once during the six month period. The burden estimates are based on data from the prior administration of the SCS. 6. An estimate of the total public burden (in hours) associated with the collection: The total burden hours for this collection is 1,380. 7. An estimate of the total annual cost burden associated with the collection, if applicable: $1,728,353. E:\FR\FM\18JNN1.SGM 18JNN1

Agencies

INTERNATIONAL TRADE COMMISSION

[Federal Register Volume 89, Number 118 (Tuesday, June 18, 2024)]
[Notices]
[Pages 51549-51550]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-13370]


-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-1377]


Certain Products Containing Tirzepatide and Products Purporting 
To Contain Tirzepatide; Notice of a Commission Determination Not To 
Review an Initial Determination Granting a Motion To Amend the 
Complaint and Notice of Investigation

AGENCY: International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission (``Commission'') has determined not to review an initial 
determination (``ID'') (Order No. 16) of the presiding administrative 
law judge (``ALJ'') granting a motion to amend the complaint and notice 
of investigation to name an additional respondent.

FOR FURTHER INFORMATION CONTACT: Edward S. Jou, Esq., Office of the 
General Counsel, U.S. International Trade Commission, 500 E Street SW, 
Washington, DC 20436, telephone (202) 205-3316. Copies of non-
confidential documents filed in connection with this investigation may 
be viewed on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. For help accessing EDIS, please email 
[email protected]. General information concerning the Commission may 
also be obtained by accessing its internet server at https://www.usitc.gov. Hearing-impaired persons are advised that information on 
this matter can be obtained by contacting the Commission's TDD 
terminal, telephone (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
on November 27, 2023, based upon a complaint filed on behalf of Eli 
Lilly and Company (``Eli Lilly'') of Indianapolis, Indiana. 88 FR 
82914-15 (Nov. 27, 2023). The complaint, as supplemented, alleges 
violations of section 337 based upon the importation into the United 
States and the sale of certain products containing tirzepatide or 
purporting to contain tirzepatide by reason of false designation of 
source and false and misleading advertising, the threat or effect of 
which is to destroy or substantially injure an industry in the United 
States, and based upon the importation into the United States, the sale 
for importation, and the sale within the United States after 
importation of certain products containing tirzepatide or purporting to 
contain tirzepatide by reason of infringement of U.S. Trademark No. 
6,809,369. Id. The complaint also alleges that a domestic industry 
exists pursuant to subsection (a)(2) of section 337. Id.
    The Commission's notice of investigation named as respondents 
Arctic Peptides LLC of Akeny, Iowa; Audrey Beauty Co. of Hong Kong, 
China; Biolabshop Limited of Lancaster, United Kingdom; Mew Mews 
Company Limited of Hong Kong, China; Strate Labs LLC of Spring, Texas; 
Steroide Kaufen of Bialystok, Poland; Super Human Store of Barcelona, 
Spain; Supopeptide of Cedar Grove, New Jersey; Triggered Supplements 
LLC of Clearwater, Florida; Unewlife of Cedar Grove, New Jersey; and 
Xiamen Austronext Trading Co., Ltd. of Fujian, China. Id. at 82915. The 
Office of Unfair Import Investigations (``OUII'') is also named as a 
party in this investigation. Id.
    Respondents Unewlife, Supopeptide, and Steroide Kaufen were 
terminated pursuant to withdrawal of the complaint. See Order No. 8 
(Mar. 7, 2024), unreviewed by Comm'n Notice (Mar. 21, 2024). 
Respondents Arctic Peptides LLC; Audrey Beauty Co., Ltd.; Biolabshop 
Limited; Mew Mews Co. Ltd.; Strate Labs LLC; Super Human Store; 
Triggered Supplements LLC (d/b/a The Triggered Brand); and Xiamen 
Austronext Trading Co., Ltd. (d/b/a AustroPeptide) have been found in 
default. See Order No. 13 (Apr. 22, 2024), unreviewed by Comm'n Notice 
(May 15, 2024).
    On May 21, 2024, the complaint and notice of investigation were 
amended to add two respondents: Fibonacci Sequence LLC d/b/a GenX 
Peptides of Houston, Texas; and Paradigm Peptides of Michigan City, 
Indiana. Order No. 12 (Apr. 22, 2024), unreviewed by Comm'n Notice (May 
21, 2024), 89 FR 46159-60 (May 28, 2024).
    On May 8, 2024, Eli Lilly filed a motion to amend the complaint and 
notice of investigation to name an additional respondent, Total 
Compounding Pharmaceuticals of Australia. On that same date, Eli Lilly 
filed a motion for leave to serve Total Compounding Pharmaceuticals by 
alternative service via email, which was granted pursuant to Order No. 
14 (May

[[Page 51550]]

13, 2024). On May 15, 2024, OUII filed a response to the motion to 
amend, which did not oppose the amendment.
    On May 17, 2024, the ALJ issued the subject ID granting the motion 
to amend the complaint and notice of investigation to name Total 
Compounding Pharmaceuticals as a respondent. The ALJ found that Eli 
Lilly had complied with the requirements of Commission Rule 210.14(b) 
(19 CFR 210.14(b)) for amendment of the complaint and notice of 
investigation. See ID at 3-6.
    No petitions for review of the subject ID were filed.
    The Commission has determined not to review the subject ID. The 
complaint and notice of investigation are hereby amended to add 
respondent Total Compounding Pharmaceuticals.
    The Commission vote for this determination took place on June 13, 
2024.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and 
in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR 
part 210).

    By order of the Commission.
    Issued: June 13, 2024.
Lisa Barton,
Secretary to the Commission.

[FR Doc. 2024-13370 Filed 6-17-24; 8:45 am]
BILLING CODE 7020-02-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.